How tumor necrosis factor protects against infection

July 11 2016

Macrophages (blue nucleus) that are infected with Leishmania major (purple) and have been stimulated with the messenger substance interleukin 4 produce arginase 1 (green). Credit: Katrin Paduch/FAU Institute of Microbiology

Tumour necrosis factor (TNF), a messenger substance in the immune system, plays an important role in triggering chronic inflammatory diseases. For this reason, TNF inhibitors are a standard form of treatment for patients with rheumatoid arthritis and certain inflammatory bowel diseases. However, TNF also protects against infection, which
means that inhibiting it can cause latent infections to resurface. Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg have now discovered a new mechanism via which TNF protects against intracellular pathogens that cause infection.

In order to defend the body against intracellular pathogens, such as the single-cell parasites Leishmania major, nitric oxide (NO) must be produced. This is formed in macrophages and other phagocytes through type 2 NO synthase (NOS2). However, the function of NOS2 is inhibited by a competing enzyme called arginase 1. In collaboration with researchers from Erlangen and beyond, the working group led by PD Dr. Ulrike Schleicher and Prof. Dr. Christian Bogdan at FAU’s Institute of Microbiology - Clinical Microbiology, Immunology and Hygiene demonstrated through cell culture experiments and an infection model that tumour necrosis factor inhibits arginase 1 synthesis, which depends on the messenger substance interleukin 4. This causes nitric oxide production to increase and suppresses the pathogens.

'As long as they can be confirmed in ongoing experiments with human cells, these findings provide a plausible explanation of the increased susceptibility to infection that occurs during anti-TNF treatments,' explains Professor Bogdan, 'In the future, concurrent use of arginase 1 inhibitors could minimise the risk of infection associated with TNF inhibition.'

The results of the study, which was partially carried out in the framework of FAU's Interdisciplinary Centre for Clinical Research and DFG Collaborative Research Centre 1181, have recently been published in the international journal Cell Reports.

More information: Ulrike Schleicher et al, TNF-Mediated Restriction of Arginase 1 Expression in Myeloid Cells Triggers Type 2 NO Synthase Activity at the Site of Infection, Cell Reports (2016). DOI: